Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Breast cancer in 2015

Academic research sheds light on issues that matter to patients

Nature Reviews Clinical Oncology volume 13, pages 67–68 (2016)Cite this article

Subjects

In 2015, academic-led trials provided evidence for safe de-escalation of adjuvant treatment in early stage breast cancer and answered important questions related to adjuvant regional irradiation and optimal first-line chemotherapy in advanced-stage disease. Furthermore, the development of novel therapies and potential tools for treatment tailoring will offer new hope to patients with breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 372, 134–141 (2015).

    Article  Google Scholar 

  2. Francis, P. A. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 372, 436–446 (2015).

    Article  Google Scholar 

  3. Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005–2014 (2015).

    Article  CAS  Google Scholar 

  4. Whelan, T. J. et al. Regional nodal irradiation in early-stage breast cancer. N. Engl. J. Med. 373, 307–316 (2015).

    Article  CAS  Google Scholar 

  5. Poortmans, P. M. et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N. Engl. J. Med. 373, 317–327 (2015).

    Article  CAS  Google Scholar 

  6. Rugo, H. S. et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J. Clin. Oncol. http://dx.doi.org/10.1200/jco.2014.59.5298 (2015).

  7. Tutt, A. et al. Abstract S3-01: The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 75, S3-01 (2015).

    Google Scholar 

  8. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).

    Article  CAS  Google Scholar 

  9. Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209–219 (2015).

    Article  CAS  Google Scholar 

  10. Emens, L. A. et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. [abstract PD1-6], Presented at the San Antonio Breast Cancer Symposium (2014).

  11. Nanda, R. et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. [abstract S1-09], Presented at the San Antonio Breast Cancer Symposium (2014).

  12. Dirix, L. Y. et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. [abstract S1-04], Presented at the San Antonio Breast Cancer Symposium (2015).

  13. Salgado, R. et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 1, 448–454 (2015).

    Article  Google Scholar 

  14. Gebhart, G. et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdv577 (2015).

Download references

Author information

Authors and Affiliations

  1. Martine J. Piccart is at the Department of Medical Oncology, Institut Jules Bordet/Université libre de Bruxelles, 1 Rue Héger-Bordet, 1000 Bruxelles, Brussels, Belgium.,

    Martine J. Piccart

  2. Isabelle Gingras is at the Department of Hematology and Oncology, Hôpital du Sacré-Cœur de Montréal/Université de Montréal, 5400 Boulevard Gouin, Montreal, Quebec H4J 1C5, Canada.,

    Isabelle Gingras

Authors
  1. Martine J. Piccart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Gingras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martine J. Piccart.

Ethics declarations

Competing interests

M.J.P. declares she is a consultant for and receives honoraria from AstraZeneca, Invivis, MSD, Novartis, Pfizer, Radius, Roche-Genentech and Synthon. I.G. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piccart, M., Gingras, I. Academic research sheds light on issues that matter to patients. Nat Rev Clin Oncol 13, 67–68 (2016). https://doi.org/10.1038/nrclinonc.2015.236

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.236

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer